Periosteal cells that had been cultured in osteogenic induction medium were treated with 0.1 to 25 µM PPARα agonist WY14643, 0.1 to 10 µM PPARγ agonist pioglitazone, 0.1 to 10 µM PPARα antagonist GW6471, or 0.1 to 10 µM PPARγ antagonist T0070907 (all from R&D Systems, Minneapolis, USA). Media were changed every 3 days and the ligands were also added at each change of the medium.
T0070907
Manufactured by R&D Systems
Sourced in United States
T0070907 is a laboratory reagent produced by R&D Systems. It is a small molecule compound used in research applications.
Automatically generated - may contain errors
Lab products found in correlation
Pioglitazone, by R&D Systems (2 mentions)
Wy 14643, by R&D Systems (1 mentions)
Gw6471, by R&D Systems (1 mentions)
Recombinant rat ifnγ, by R&D Systems (1 mentions)
Human ifn γ, by Thermo Fisher Scientific (1 mentions)
Dimethyl sulfoxide (dmso), by Merck Group (1 mentions)
Recombinant human il 1β, by R&D Systems (1 mentions)
3 protocols using t0070907
1
PPARα and PPARγ Modulation in Osteogenesis
2
Osteogenic Differentiation with PPARγ Modulators
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Periosteal cells that had been cultured in osteogenic induction medium were treated with 5 and 10 µM concentrations of either PPARγ agonist pioglitazone or PPARγ antagonist T0070907 (all from R&D Systems, Minneapolis, MN, USA). Media were changed every 3 days, and the PPARγ agonist or antagonist was also added at each change of the medium.
3
Cytotoxicity Assay for Endocrine Disruptors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Chemicals used herein were purchased as follows: BPA (Cat. No. 239658), TBT (Cat. No. T50202), PFOA (Cat. No. 77262), TPP (Cat. No. 241288), TCS (Cat. No. PHR1338) and DDE (Cat. No. 123897) were obtained from Sigma-Aldrich (Barcelona, Spain). All stock solutions were weekly prepared by dissolution in 100% cell-culture grade, sterile-filtered DMSO (Sigma-Aldrich, Barcelona, Spain; Cat No D2650) and stored at −20 °C between uses. ICI 182,780 (Cat. No. 1047) was obtained from Tocris Cookson Ltd. (Avonmouth, UK). T0070907 (Cat. No. HY-13202) and rosiglitazone (Cat. No. HY-117287) were obtained from MedChem Express (Monmouth Junction, NJ, USA). Due to its short half-life, T0070907 was redosed every 8–10 h. Recombinant human IL-1β and recombinant rat IFNγ were obtained from R&D Systems (Abingdon, UK); (R&D Systems); human IFNγ was obtained from PeproTech (Rocky Hill, NJ). The concentrations of cytokines used herein were selected based on previous dose-response experiments performed in human and rat β-cells [88 (link),89 (link),90 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!